Dr Stuart CollinsonChairman and CEO
Dr Collinson’s career includes executive leadership and board roles with public and private life science companies in the US and Europe, and as a partner with a venture capital firm.
He has served on the boards of companies including Affinium Pharmaceuticals (acquired by Debiopharm), Cabrellis Pharmaceuticals (acquired by Pharmion, now part of Celgene), Conforma Therapeutics (acquired by Biogen), Essentialis (acquired by Capnia, now Soleno Therapeutics), GeneOhm Sciences (acquired by Becton Dickinson), NovaCardia (acquired by Merck & Co), and Vertex Pharmaceuticals.
As a life science partner with Forward Ventures, Dr Collinson has led investments in numerous biopharmaceutical companies. Previously, he was Chairman and CEO of Aurora Biosciences (acquired by Vertex Pharmaceuticals). He held senior management positions at GlaxoWellcome (now GlaxoSmithKline) and Baxter International, and was a consultant with The Boston Consulting Group.
Dr Collinson received an MBA from Harvard Business School (Fulbright Scholar), a DPhil (PhD) in Physical Chemistry from the University of Oxford.
Dr Georg TerstappenChief Scientific Officer
Georg Terstappen has 25 years’ experience in pharmaceutical R&D obtained in leading positions in international companies including Bayer, GlaxoWellcome, GlaxoSmithKline (GSK), Abbott / AbbVie, and in the biotech industry where he was Co-founder and CSO of a ‘start-up’ drug discovery company, Siena Biotech S.p.A. Prior to joining OxStem, Georg was Head of Discovery Biology at AbbVie in Ludwigshafen (Germany), and most recently Head of Platform Technologies & Science China at GSK's R&D Centre in Shanghai, with responsibility for preclinical drug development.
In the European R&D framework Georg has held leading positions: He was Vice-Chair of the Innovative Medicines Strategy Group (InnoMedS) in the context of EFPIA and IMI (Innovative Medicines Initiative) and is a founding member and Co-Chair of the Strategic Governing Group for Neurodegeneration. In addition, he was also for more than ten years Adjunct Professor at several European universities and leader of European-wide research programs funded by the EU and public-private partnerships funded by IMI.
Dr Andy MulvaneyChief Operating Officer
Dr. Andy Mulvaney has 17 years’ biotech experience in operational, business development and alliance management roles, most recently as Vice President, Business Development at Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM). In 2003 he co-founded VASTox Ltd., now Summit Therapeutics plc, with Professor Stephen Davies and Professor Dame Kay Davies to develop utrophin modulation as a disease-modifying strategy for Duchenne Muscular Dystrophy. Andy initially served as Chief Operating Officer and in October 2004 was instrumental in the successful IPO of VASTox on the AIM segment of the London Stock Exchange. From 2006, Andy focussed on strategic partnering and completed a number of global and regional licensing transactions, acquisitions and divestments, with deal values exceeding $1.3Bn. Andy is a member of the Pharmaceutical Licensing Group.
Andy was a postdoctoral fellow in the Dyson Perrins Laboratory, University of Oxford, working with Professor Stephen Davies, establishing the group’s activities in utrophin modulation, chemical genetics and combinatorial chemistry. Andy holds a Ph.D. from Cardiff University where he studied homogeneous catalysis using organometallic complexes, having been awarded a prestigious fully funded scholarship by open competition from ICI.
Dr Carolyn PorterChief Business Officer
Dr. Carolyn Porter has 16 years’ experience spanning management, commercial and business development roles in the Biotech, Pharma, Finance and University sectors. In her most recent role at Oxford University Innovation as Deputy Head of Technology Transfer she led or mentored the formation of 16 spin-out companies collectively raising £52M in seed financing and concluded some of the company’s largest licensing deals. Carolyn has held board positions representing the University in 5 spin-out companies including OxStem. Prior to this Carolyn held senior business development roles in Novartis Vaccines (Head of Search & Evaluation in Europe) and Chiron Vaccines (Business Development Director) working on in/out licensing, acquisitions and strategic alliances with deal values in excess of $1bn. Her earlier career included working as a biotech analyst and then in Corporate Finance at Ernst & Young where she assisted companies with fundraising, acquisitions and company sales.
Carolyn previously held post-doctoral positions at Oxford University in Biochemistry and Immunology. She has a PhD in Immunology from Trinity College Dublin, a first-class honors degree in Pharmacology from University College Dublin and an MBA from Warwick Business School. She is a member of the Licensing Executives Society and the Pharmaceutical Licensing Group.
Raymond SpencerChief Financial Officer
Raymond Spencer, CFO has over 30 years’ experience as a senior financial officer in biotech. For 12 years he was the CFO of LSE listed Antisoma plc. Whilst at Antisoma he was instrumental in completing the IPO in 1998, several fund-raising rounds that totalled over £100 million, the acquisition of two private US biotech companies and the closing of three licensing deals with big pharma with total upfront licence fees exceeding £100m.
Raymond was CFO for AIM listed Summit plc for 5 years to July 2014 having completed a restructuring of the company, raised over £20m in equity financing and the acquisition of the Oxford University spin-out MuOx Ltd. Raymond is currently part-time founder, Director and CFO of MGB-Biopharma Ltd, which has raised over £6m from angel investors, Scottish Enterprise and won a Biomedical Catalyst award from Innovate UK to progress drugs for treatment of anti-microbial resistance. He has also established his own consultancy company, Bio-CFO Ltd providing services to biotech and cleantech companies. Raymond qualified as a chartered accountant with KPMG in 1979.